GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectar Biosciences Inc (FRA:NV4) » Definitions » Gross Profit

Cellectar Biosciences (FRA:NV4) Gross Profit : €0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Cellectar Biosciences Gross Profit?

Cellectar Biosciences's gross profit for the three months ended in Mar. 2024 was €0.00 Mil. Cellectar Biosciences's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Cellectar Biosciences's gross profit for the three months ended in Mar. 2024 was €0.00 Mil. Cellectar Biosciences's Revenue for the three months ended in Mar. 2024 was €0.00 Mil. Therefore, Cellectar Biosciences's Gross Margin % for the quarter that ended in Mar. 2024 was N/A%.

Cellectar Biosciences had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Cellectar Biosciences Gross Profit Historical Data

The historical data trend for Cellectar Biosciences's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectar Biosciences Gross Profit Chart

Cellectar Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cellectar Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cellectar Biosciences's Gross Profit

For the Biotechnology subindustry, Cellectar Biosciences's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectar Biosciences's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectar Biosciences's Gross Profit distribution charts can be found below:

* The bar in red indicates where Cellectar Biosciences's Gross Profit falls into.



Cellectar Biosciences Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Cellectar Biosciences's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Cellectar Biosciences's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Cellectar Biosciences's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Cellectar Biosciences  (FRA:NV4) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Cellectar Biosciences had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Cellectar Biosciences Gross Profit Related Terms

Thank you for viewing the detailed overview of Cellectar Biosciences's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectar Biosciences (FRA:NV4) Business Description

Traded in Other Exchanges
Address
100 Campus Drive, Florham Park, NJ, USA, 07932
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.

Cellectar Biosciences (FRA:NV4) Headlines

No Headlines